Drug development and delivery solutions provider Patheon has completed the acquisition of a manufacturing facility from Roche in Florence, South Carolina, US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company started integrating the site into its network, which will add a 300,000ft² facility with manufacturing capacity for active pharmaceutical ingredient (API) ranging from development to manufacturing services.

The addition of this site will enable Patheon to expand its capacity for manufacturing highly potent compounds and also supports solid state chemistry, micronisation and future commercial spray drying.

Patheon drug substance services president Lukas Utiger said: “We are extremely pleased to add this facility to the Patheon network and the talented professionals that will support a wide range of drug substance services.

“Patheon has extensive experience and success integrating new sites into our global network and quickly leveraging the capabilities for the benefit of our clients.”

"Patheon has extensive experience and success integrating new sites into our global network and quickly leveraging the capabilities for the benefit of our clients."

The pharmaceutical manufacturing facility’s production space features reactors ranging from 50l to 11,000l capable of producing multiple products simultaneously.

The site additionally provides flexible operations, allowing the company to adapt to new production needs quickly.

Serving as Patheon’s US API operation for commercial scale and mid-scale API production, the site will also improve the company’s pharma presence in the US market.

The latest acquisition is the company’s sixth in the last five years and supports its plans to create an integrated provider of pharma development and manufacturing services.

Image: Patheon adds 300,000ft² manufacturing site in Florence, South Carolina, US, to its global network. Photo: courtesy of Business Wire.